Hoshino, Shota
Matsuda, Satoru
Kawakubo, Hirofumi
Yamaguchi, Shigeo
Nakamura, Kohei
Aimono, Eriko
Matsui, Kazuaki
Irino, Tomoyuki
Fukuda, Kazumasa
Nakamura, Rieko
Okita, Hajime
Nishihara, Hiroshi
Takeuchi, Hiroya
Kitagawa, Yuko
Article History
Received: 2 June 2022
Accepted: 4 June 2022
First Online: 18 June 2022
Disclosure
: Yuko Kitagawa received lecture fees from Chugai Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd, Asahi Kasei Pharma Corporation, Otsuka Pharmaceutical Factory, Inc., Shionogi & Co., Ltd., Nippon Covidien, Inc., Ono Pharmaceutical Co., Ltd., and Bristol-Myers Squibb K.K, and was supported by grants from Chugai Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd, Yakult Honsha Co., Ltd., AsahiKasei Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Tsumura & Co., Kyouwa Hakkou Kirin Co., Ltd., Dainippon Sumitomo Pharma Co., Ltd., EA Pharma Co., Ltd., Astellas Pharma, Inc., Toyama Chemical Co., Ltd., Medicon, Inc., Kaken Pharmaceutical Co. Ltd., Eisai Co., Ltd., Otsuka Pharmaceutical Factory, Inc., Teijin Pharma, Ltd., Nihon Pharmaceutical Co., Ltd., and Nippon Covidien Inc. Yuko Kitagawa held an endowed chair provided by Chugai Pharmaceutical Co., Ltd. and Taiho Pharmaceutical Co., Ltd, outside the submitted work. The remaining authors have no conflicts of interest.